SCHEMBL6500852

SCHEMBL6500852

O=C(c1cccc(C(F)(F)F)c1)C(Br)c1ccncc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.56
VNN1 O95497 1/20 0.49
NPSR1 Q6W5P4 2/20 0.46
TSHR P16473 2/20 0.45
ALOX15 P16050 1/20 0.45
CASP1 P29466 1/20 0.45
HSD17B10 Q99714 1/20 0.45
BRAF P15056 1/20 0.45
SRD5A2 P31213 1/20 0.44
TLR7 Q9NYK1 2/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
GSK3B P49841 1/20 0.43
P2RX1 P51575 1/20 0.43
LMNA P02545 1/20 0.43
CNR2 P34972 1/20 0.42
ACHE P22303 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6282484 0.99 CES2 (0.55) CES2VNN1NPSR1TSHRALOX15
SCHEMBL7149547 0.84 GSK3B (0.62) CES2SRD5A2TLR7GSK3B
SCHEMBL6601858 0.83 CES2 (0.50) CES2NPSR1TSHRALOX15CASP1
Bromide SCHEMBL6284163 0.82 GSK3B (0.60) CES2SRD5A2TLR7GSK3B
Bromide SCHEMBL3888908 0.82 CES2 (0.49) CES2NPSR1TSHRALOX15CASP1
Bromide SCHEMBL6285189 0.80 CES2 (0.51) CES2TSHRKMT2AMEN1
SCHEMBL3361277 0.79 CES2 (0.65) CES2NPSR1SRD5A2KMT2AMEN1
SCHEMBL7149123 0.78 TDP1 (0.50) NPSR1ALOX15KMT2AMEN1LMNA
SCHEMBL7143390 0.78 NT5E (0.52) VNN1HSD17B10KMT2ALMNA
SCHEMBL27627736 0.77 CES2 (0.62) CES2NPSR1SRD5A2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 CES2 4154/4885VNN1 4053/4885NPSR1 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.